Abstract:Background: Sustainability and the ability to maintain the right to health, with the guarantee of access to quality medicines and health services, have been a great challenge for countries with universal health systems. The great technological advances bring with it an expressive increase in the expenditures of the health systems, especially those directed towards the acquisition of high-cost drugs, which are still under patent protection, have a high cost and, in some cases, present uncertainties about their effectiveness and safety. As a way of maintaining the proper functioning of the systems and guaranteeing access to these medicines, some countries started to negotiate discounts with manufacturing companies. Pricing agreements have been adopted by developed countries with the objective of reducing their spending on high-cost medicines and, although they represent an opportunity for better negotiation with the industries, they violate the principle of transparency that regulates the world market. However, the existence of confidentiality agreements has meant that the declared prices are not the actual prices, unfairly harming the countries that use these price lists as beacons in their systems. Methods: Representatives of health, judicial, legislative, patient organizations and academics from eight countries in Latin America and South Korea participated in a meeting in September 2017 in Chile to discuss price confidentiality agreements and the impact on public health policies. During the meeting, participants were presented with a hypothetical case to subsidize the discussion on the topic. Divided into groups, participants should propose recommendations for the problem by pointing out the pros and cons if each proposed recommendation was adopted. The groups were then confronted by a simulated jury and finally issued a single and final recommendation for the problem. Results: The topic was widely discussed and recommendations were raised by the participants. Among them, it is worth noting the elaboration of norms that regulate the negotiations of prices between the countries bringing transparency and harmony in the adopted conducts. In addition, the possible consequences and potential impacts of confidentiality on drug prices and inputs, such as information asymmetry and inequity of access between countries, were pointed out. Conclusion: Despite there are efforts to make price negotiations more transparent, there is still no well-established standardization that promotes a well-functioning market. Confidentiality agreements hamper the fairness of access to essential health products.

[The relationship between medicine and medical suppliers]

Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote

[Conflicts of Interest in Research and Clinical Practice]

Ethical issues of medical schools and their academic departments accepting gifts from pharma

[Is it pertinent to investigate the relations between physicians and the drug industry]

Biomedical Researchers' Conflict of Interest And Solution

Discrepancies in Conflict-of-Interest Disclosures Among Physicians Receiving Compensation for Monoclonal Antibody Drugs

On Academic Conflict in Medical Research Articles

Physician-industry collaboration: conflicts of interest and the imputation of motive

Rebalancing commercial and public interests in prioritizing biomedical, social and environmental aspects of health through defining and managing conflicts of interest

Unpicking influence and conflicts of interest in prescribing

'On being both professional and human': a response

Extent of physician-pharmaceutical industry interactions in low- and middle-income countries: a systematic review

Confidentiality agreements: a challenge in market regulation

Industry influence in healthcare harms patients: myth or maxim?

The pharmaceutical company-healthcare relationship: much ado about something

The ICMJE Recommendations and pharmaceutical marketing – strengths, weaknesses and the unsolved problem of attribution in publication ethics

Relationships among commercial practices and author conflicts of interest in biomedical publishing

Effect of revealing authors' conflicts of interests in peer review: randomized controlled trial

Accessibility and transparency of editor conflicts of interest policy instruments in medical journals

Conflicts of interest in clinical practice: lessons learned from cardiovascular medicine